Statins exert a number of beneficial effects on endothelial function and atherosclerotic plaque, modulating oxidative stress and inflammation, with subsequent, well documented, primary and secondary prevention of coronary artery disease. Periprocedural myocardial infarction and contrast induced nephropathy, after percutaneous coronary intervention (PCI), are associated with a worse outcome on long term follow-up. In the ARMYDA study, pretreatment with statins before elective PCI reduces periprocedural myocardial infarction in patients with stable angina. Moreover, the ARMYDA ACS was the first randomized, prospective trial that demonstrated that an acute loading with a high dose of atorvastatin prevents myocardial damage in patients with unstable syndromes undergoing early (<48 hours) coronary angiography and consequent angioplasty. Statins could also have beneficial effects by reducing expression of adhesion molecules in endothelial cells (ICAM-1 and E-Selectin) as demonstrated in the ARMYDA-CAMS study. Furthermore, patients receiving statins at the time of procedure show a significantly reduced incidence of contrast-induced nephropathy. All this evidence may strongly influence the clinical practice of an interventional cardiologist.
Abdelmeguid, A.E., Topol, E.J., Whitlow, P.L., Sapp, S.K. and Ellis, S.G. (1996) Significance of mild transient release of creatine-kinase MB fraction after percutaneous coronary interventions. Circulation94: 1528-1536.
2.
Bellosta, S.,Via, D., Canavesi, M., Pfister, P., Fumagalli, R., Paoletti, R. et al. (1998) HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol18: 1671-1678.
3.
Bonetti, P.O., Lerman, L.O., Napoli, C. and Lerman, A. (2003) Statin effects beyond lipid lowering-are they clinically relevant? Eur Heart J24: 225-248.
4.
Brener, S.J., Ellis, S.G., Schneider, J., Topol, E.J. (2002) Frequency and long-term impact of myonecrosis after coronary stenting. Eur Heart J23: 869-876.
5.
Briel, M., Schwartz, G.G., Thompson, P.L., de Lemos, J.A., Blazing, M.A., van Es, G.A. et al. (2006) Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. JAMA295: 2046-2056.
6.
Chan, A.W., Bhatt, D.L., Chew, D.P., Quinn, M.J., Moliterno, D.J., Topol, E.J. et al. (2002) Early and sustained survival benefit associated with statin therapy. Circulation105: 691-696.
7.
Chan, A.W., Chew, D.P., Bhatt, D.L., Moliterno, D.J., Topol, E.J., Ellis, S.G. et al.(2004) Relation of inflammation and benefit of statins after percutaneous intervention on frequency of periprocedural myocardial injury. Am J Cardiol94: 1363-1366.
8.
Chang, S.M.,Yazbek, N. and Lakkis, N.M. (2004) Use of statins prior to percutaneous coronary intervention reduces myonecrosis and improves clinical outcome. Catheter Cardiovasc Interv62: 193-197.
9.
Davignon, J. (2004) Beneficial cardiovascular pleiotropic effects of statins. Circulation109: 39-43.
10.
Desmet, W., Dens. J., Coussement, P. and Van de Werf, F. (2002) Does adenosine prevent myocardial micronecrosis following percutaneous coronary intervention? The ADELINE pilot trial. Heart88: 293-295.
11.
Gruberg, L., Mintz, G.S., Mehran, R., Gangas, G., Lansky, A.J., Kent, K.M. et al. (2000) The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. JACC36: 1542-1548.
12.
Hernández-Perera, O., Pérez-Sala, D., Navarro-Antolín, J., Sánchez-Pascuala, R., Hernández, G., Díaz, C. et al. (1998) Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest101: 2711-2719.
13.
Herrmann, J., Lerman, A., Baumgart, D., Volbracht, L., Schulz, R., von Birgelen, C. et al. (2002) Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. Circulation106: 2180-2183.
14.
Hinoi, T., Matsuo, S., Tadehara, F., Tsujiyama, S. andYamakido, M. (2005) Acute effect of atorvastatin on coronary circulation measured by transthoracic
15.
Doppler echocardiography in patients without coronary artery disease by angiography . Am J Cardiol96: 89-91.
16.
Ichiki, T., Takeda, K., Tokunou, T., Iino, N., Egashira, K., Shimokawa, H. et al. (2001) Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol21: 1896-1901.
17.
Ioannidis, J.P.A., Karvouni, E. and Katritis, D.G. (2003) Mortality risk conferred by small elevations of creatinine kinase-MB isoenzyme after percutaneous intervention. J Am Coll Cardiol42: 1406-1411.
18.
Khanal, S., Attallah, N., Smith, D.E., Kline-Rogers, E., Share, D., O'Donnell, M.J. et al. (2005) Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Medicine118: 843-849.
19.
Kinlay, S., Schwartz, G.G., Olsson, A.G., Rifai, N., Leslie, S.J., Sasiela, W.J. et al. (2003) Myocardial ischemia reduction with aggressive cholesterol lowering study investigators. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation108: 1560-1566.
20.
Kurz, D.J., Naegeli, B. and Bertel, O. (2000) A double-blind, randomized study of the effect of immediate intravenous nitroglycerin on the incidence of post-procedural chest pain and minor myocardial necrosis after elective coronary stenting . Am Heart J. 139: 35-43.
21.
Lindsay, J., Apple, S., Pinnow, E.E., Gevorkian, N., Gruberg, L., Satler, L.F. et al. (2003) Percutaneous coronary intervention-associated nephropathy foreshadows increased risk of late adverse events in patients with normal baseline serum creatine. Cathet Cardiovasc Intervent59: 338-343.
22.
Long-term Intervention with Paravstatin in Ischaemic Disease (LIPID) study group. (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med339: 1349-1357.
23.
Morikawa, S., Takabe, W., Mataki, C., Kanke, T., Itoh, T., Wada, Y. et al. (2002) The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells. J Atheroscler Thromb9: 178-183.
24.
Murphy, S.W., Barrett, B.J. and Parfrey, P.S. (2000) Contrast nephropathy. J Am Soc Nephrol11: 177-182.
25.
Pasceri, V., Patti, G., Nusca, A., Pristipino, C., Richichi, G., Di Sciascio, G. et al. (2004) ARMYDA Investigators. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation110: 674-678.
26.
Patti, G., Chello, M., Pasceri, V., Colonna, D., Nusca, A., Miglionico, M. et al. (2006) Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy. J Am Coll Cardiol48: 1560-1566.
27.
Patti, G., Nusca, A., Chello, M., Pasceri, V., D'Ambrosio, A., Vetrovec, G.W. et al. (2008) Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol101: 279-285.
28.
Patti, G., Pasceri, V., Colonna, G., Miglionico, M., Fischetti, D., Sardella, G. et al. (2007) Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol49: 1272-1278.
29.
Rihal, C.S., Textor, S.C., Grill, D.E., Berger, P.B., Ting, H.H., Best, P.J. et al. (2002) Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation105: 2259-2264.
30.
Sacks, F.M., Pfeffer, M.A., Moye, L.A., Rouleau, J.L., Rutherford, J.D., Cole, T.G. et al. (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: cholesterol and recurrent events trial investigators. N Engl J Med335: 1001-1009.
31.
Sanguigni, V., Pignatelli, P., Lenti, L., Ferro, D., Bellia, A., Carnevale, R. et al. (2005) Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients . Circulation111: 412-419.
32.
Scandinavian Simvastatin Survival Study (4S). ( 1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet344: 1383-1389.
33.
Schwartz, G.G., Olsson, A.G., Ezekowitz, M.D., Ganz, P., Oliver, M.F- Waters, D. et al. (2001) Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: a randomized controlled trial. JAMA285: 1711-1718.
34.
The EPISTENT Investigators. (1998) Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet352: 87-92.
35.
Turer, A.T., Mahaffey, K.W., Gallup, D., Weaver, W.D., Christenson, R.H., Every, N.R. et al. (2005) Enzyme estimates of infarct size correlate with functional and clinical outcomes in the setting of ST-segment elevation myocardial infarction. Curr Control Trials, Cardiovasc Med6: 12-15.
36.
Wang, F.W., Osman, A., Otero, J., Stouffer, G.A., Waxman, S., Afzal, A. et al. (2003) Distal myocardial protection during percutaneous coronary intervention with an intracoronary beta-blocker. Circulation107: 2914-2919.
37.
Wassmann, S., Faul, A., Hennen, B., Scheller, B., Böhm, M., Nickenig, G. et al. (2003) Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function. Circ Res93: e98-103.
38.
Xenos, E.S., Stevens, S.L., Freeman, M.B., Cassada, D.C. and Goldman, M.H. (2005) Nitric oxide mediates the effect of fluvastatin on intercellular adhesion molecule-1 and platelet endothelial cell adhesion molecule-1 expression on human endothelial cells. Ann Vasc Surg19: 386-392.
